Dr. William Newman spoke with Cancer Network about the roles of epigenetic silencing in heritable cancer syndromes.
Dr. Denise Faustman spoke with Cancer Network about TNFR2 and its emerging role in understanding regulatory T-cell behavior.
Oncologists now have some clarification on the use of moderate hypofractionation and ultrahypofractionation from ASTRO, ASCO, and the AUA.
A study of more than 350 hospitals found variations in readmission and mortality rates after cancer surgical procedures.
Long-term data from the phase III HELIOS trial indicates ibrutinib plus bendamustine and rituximab improve survival outcomes in CLL patients.
Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.
A study shows that lower doses of ibrutinib after a full-dose cycle may be enough for continued biological activity.
Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC.
The SOLAR-1 trial tested whether the PI3K inhibitor alpelisib improved outcomes in HR+, HER2− breast cancer patients.